New and emerging therapeutic agents for the treatment of fibromyalgia: an update
1IGERT Program in Functional Genomics, Graduate School of Biomedical Sciences, University of Maine and The Jackson Laboratory, Bar Harbor, Maine, USA.
Abstract:
Fibromyalgia (FM) is a chronic widespread pain condition that is estimated to affect 5 million US adults. Several molecular pathophysiologies are thought to contribute to the symptoms of FM, complicating the development of effective clinical management techniques. It is now known that abnormalities in both nociceptive and central pain processing systems are necessary (but perhaps not sufficient) to condition the onset and maintenance of FM, producing associated neuropsychologic symptoms such as pronounced fatigue, sleep abnormalities, cognitive difficulties, stress sensitivity, anxiety, and depression. Current treatment strategies are focused primarily on correcting the pathophysiologic mechanisms underlying these nervous system abnormalities. Clinical studies demonstrate the safety and efficacy of three drugs recently approved for the treatment of FM: pregabalin (an alpha-2-delta ligand), and duloxetine and milnacipran (serotonin/norepinephrine reuptake inhibitors). This review describes these pharmaceuticals in detail and discusses their current roles in FM management.
Insights
Fibromyalgia (FM) is a widespread pain condition affecting millions. Approved medications like pregabalin, duloxetine, and milnacipran offer new treatment options by targeting nervous system abnormalities.
Area of Science:
- Neurology
- Pharmacology
Background:
- Fibromyalgia (FM) is a chronic pain disorder affecting 5 million US adults.
- Pathophysiology involves nociceptive and central pain processing abnormalities.
- Associated symptoms include fatigue, sleep issues, cognitive difficulties, and mood disorders.
Purpose of the Study:
- To review the pathophysiology of fibromyalgia.
- To discuss recently approved pharmacologic treatments for FM.
- To detail the roles of pregabalin, duloxetine, and milnacipran in FM management.
Main Methods:
- Literature review of clinical studies.
- Analysis of safety and efficacy data for approved FM medications.
- Description of drug mechanisms of action.
Main Results:
- Pregabalin (alpha-2-delta ligand) is approved for FM treatment.
- Duloxetine and milnacipran (serotonin/norepinephrine reuptake inhibitors) are also approved.
- These drugs demonstrate safety and efficacy in clinical studies.
Conclusions:
- Current FM management focuses on nervous system abnormalities.
- Approved medications target specific pathophysiologic mechanisms.
- Pregabalin, duloxetine, and milnacipran represent significant advancements in FM pharmacotherapy.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...